| Adalimumab n = 17 | Placebo n = 15 |
---|---|---|
Age (years; Mean +/-SD) | 15.1 +/- 1.5 | 15.5 +/- 1.7 |
Gender female (%) | 7 (41%) | 8 (53%) |
Duration since diagnosis (years; Mean +/- SD) | 0.9 +/- 1.1 | 2.5 +/- 2.8 |
Duration since first symptoms (years; Mean +/-SD) | 2.3 +/- 1.5 | 4.0 +/- 3.1 |
Family history with ankylosing spondylitis | 6 (35.3%) | 6 (40.0%) |
HLA B27 positive | 10/14 (71.4%) | 9/11 (81.8%) |
Previous treatment courses | Â | Â |
Conventional NSAIDs | 17 (100%) | 15 (100%) |
Coxibes | 5 (29.4) | 4 (26.7) |
Corticosteroids, oral Corticosteorids, intraarticular | 4 (23.5) 6 (35.3) | 9 (60%) # 6 (40) |
Methotrexate | 4 (23.5) | 6 (40) |
Sulfasalazine | 4 (23.5) | 7 (46.7) |
Concomitant medication | Â | Â |
Conventional NSAIDs | 14 (82.4%) | 14 (93.3%) |
Coxibes | 1 (5.9%) | Â |
Corticosteroids, oral | 3 (17.6%) | 5 (33.3%) |
No. of active joints mean (SD) | 3.8 (2.6) | 4.9 (5.1) |
No. of joints with LOM mean (SD) | 2.2 (2.6) | 4.7 (5.9) |
BASDAI Spinal inflammation mean (SD) | 4.29 (1.97) | 5.24 (2.34) |
BASDAI Total score mean (SD) | 4.75 (1.30) | 5.45 (1.50) |
Back pain at any time mean (SD) | 6.0 (1.4) | 7.2 (1.6)* |
Back pain at night mean (SD) | 5.3 (2.4) | 4.9 (2.6) |
Pain score mean (SD) | 5.65 (1.58) | 6.07 (1.46) |
Patient's Global NRS mean (SD) | 5.94 (1.85) | 6.87 (1.88) |
Physical function (BASFI) mean (SD) | 3.85 (1.80) | 4.17 (2.31) |
Physical function (CHAQ) mean (SD) | 0.993 (0.420) | 0.958 (0.397) |
Physician's Global NRS mean (SD) | 5.59 (1.77) | 6.07 (2.19) |
Parent's Global NRS mean (SD) | 5.94 (1.39) | 6.07 (2.19) |
Back pain at any time mean (SD) | 6.0 (1.4) | 5.60 (2.06) |